Overview

The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Patients who tear their ACL are at high risk for developing arthritis (post-traumatic osteoarthritis-PTOA) just 10 years later. Joint bleeding and inflammation contribute to deterioration of joint health. This study will determine whether treatment with Tranexamic Acid (TXA), an FDA approved medication that reduces bleeding right after ACL injury and reconstructive surgery reduces inflammation and improves joint health as a new strategy to prevent or delay the onset of PTOA.
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborator:
United States Department of Defense
Treatments:
Tranexamic Acid